INTRODUCTION
indurated plaques distributed over the malar region, angle of mandible and chin (Figures 1A and 2B). There was no associated erythema. The lesions were non-t ender and no nulcerative. Superficial sensations were intact. There was no peripheral nerve trunk thickening. Mucous membranes were unremarkable. Clinically, there was no hepatosplenomegaly. No cardiac abnormality was detected. Examination of chest and nervous system did not reveal any abnormality. A microscopical examination of Geimsa-stained smear prepared fro m biopsy material demonstrat ed t he amast igot e fo rms of leishmania parasites (Figure 2 ).
We made a clinical diagnosis favouring PKDL based on history of taking treatment for prolonged fever two years ago, patient's place of origin, site of rash, time -period of onset of rash and morphology of the rash. Other possibilities like leprosy, sarcoidosis, sclero derma and progressive macular hypomelanosis were excluded on diagnostic testing. The diagnosis was confirmed by presence of amastigote forms of leismania parasites in biopsy material from the lesions. 
DISCUSSION
PKDL was first clinically described from Bengal in 1922. 2 PKDL is a dermatosis that usually occurs after visceral leishmaniasis caused by Leishmania donovani and characterized by diverse dermal lesions from hypopigmented pinpoint marks, erythematous papules, to nodules. The dermal lesions appear in individuals who are otherwise asymptomat ic (in whom the visceral infection disappears), usually months to years after occurrence and effective treatment for classic kala-azar. 3 PKDL is mainly found in India (5-10%), Sudan (50%), and Nepal after incomplete or partial treatment o f VL cases with sodium stibogluconate. In India, 20% of cases of PKDL have no history of VL and its treatment, but on investigation, Leishmania donovani (LD) bodies can be shown in skin snips or biopsy. This type of skin lesion of PKDL may develop in asymptomatic cases of VL who had infection in the past where no kala-azar manifestations are seen.
Cases of PKDL are of co nsiderable epidemiologic importance, because these act as reservoirs of parasites. Transmission of parasite from PKDL cases to other individuals by infected phlebotomine sandflies may have been the cause of massive epidemic of kala-azar in Bihar in the 1970s. 4 It is also found in Africa (2%) but rare in China. No cases have been reported from Mediterranean areas and Central and South America. 5 Poverty, overcrowding, malnutrition, polygamy, illiteracy, and poor domestic conditions facilitate the growth of this disease, which is a major public health problem in India. 6 PKDL probably has an important role in interepidemic periods of VL, acting as a reservoir for parasites. There is increasing evidence that the pathogenesis is largely immunologically mediated; high concentrations of interleukin 10 in the peripheral blood of VL patients predict the development of PKDL 2 . During VL, interferon-gamma (IFN-) is no t pro duced by peripheral blood mononuclear cells. After treatment of VL, peripheral blood mononuclear cells start producing interferon ã, which coincides with the appearance of PKDL lesions due to IFN-ã producing cells causing skin inflammation as a reaction to persisting parasites in the skin. PKDL is essentially a clinical diagnosis, because the dermato-pathological sampling of patients is impractical, and there is lack of definitive laboratory sampling. Demonstration of LD bodies in the slit smear or by culture of the skin tissue is considered to be the gold standard for diagnosis of PKDL. 7 Molecular methods like real-time polymerase chain reaction (PCR) are expensive, cumbersome, and require trained personnel and costly equipment. 8 Treatment is always needed in Indian variety of PKDL and the condition is known for its refractoriness to various modalit ies of treatment. Antimonial compounds like sodium stibogluconate is the drug of choice for the treatment of VL 9 . Usually, it is administered 20 mg/kg/day for 30 days parenterally upto 120 days. Sodium stibogluconate which used to be a very potent drug for treatment of VL. However, resistance to this drug has emerged and the cure rate in the endemic districts of Bihar is presently as low as 30%-40% with this drug. 10 Moreover, its prolonged administration, as required in PKDL, can limit it s use, particularly because of its cardiotoxicity. However, the drug is cheap and is readily available. Our patient, though hailing from Bihar where resistance to this drug is widely present, responded satisfactorily to treatment with sodium stibogluconate.
Pentamidine isethionate is imported for use in PKDL. Its limiting factors are expense and unacceptable toxicity of causing irreversible diabetes mellitus. Amphotericin-B, both imported and indigenously available, has been used for a considerable length of time with a high efficacy rate. Repeated co urses o f amphotericin B have been found to be superior to sodium stibogluconate 11 for treatment of PKDL, with a smaller duration in the dose of 1mg/kg body weight i.v. infusion daily or alternate day for 15-20 infusions. Dose can be increased in patients with incomplete response with 30 injections. Liposomal Amphotericin-B in the dose of 2.5 mg/kg body weight is another alternative but is expensive. 12 The only oral drug, which is effective, is miltefosine in the dose of 2.5 mg / kg / day for 28 days with 95% efficacy rates 13 . Inj. paromomycin 15 mg/kg body weight can be used for about 3 weeks. Development of oral sitamaquine may augur well for future combination therapies.
In conclusion, we feel that other than the districts of North Bihar where resistance to pentavalent compounds is found in 30%-40%, in other endemic regions, in a resource poor country like India, compounds like sodium stibogluconate will still remain the first-line therapy of PKDL. Oral miltefosine is available in Bihar National Leishmaniasis control programme but its prolonged half-life raises concern for emergence of resistance. So, it should be judiciously used, to remain a potent option for resistant cases.
